Review
Open access
Jul 2026
Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas
The mechanisms underlying primary and secondary refractoriness to conventional single-targeting CAR-T therapies for B cell lymphomas are discussed and the ongoing challenges with existing CAR constructs are explored.
Toshali Pandey, D. Samat, Saurabh Dahiya et al.
· Frontiers in Immunology · 1 citation